Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Heron Therapeutics (HRTX) Leases (2019 - 2025)

Heron Therapeutics' Leases history spans 9 years, with the latest figure at $708000.0 for Q3 2025.

  • For Q3 2025, Leases fell 79.59% year-over-year to $708000.0; the TTM value through Sep 2025 reached $708000.0, down 79.59%, while the annual FY2024 figure was $2.8 million, 48.75% down from the prior year.
  • Leases reached $708000.0 in Q3 2025 per HRTX's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $15.6 million in Q1 2021 to a low of $708000.0 in Q3 2025.
  • Average Leases over 5 years is $7.0 million, with a median of $6.5 million recorded in 2023.
  • Peak YoY movement for Leases: decreased 14.5% in 2021, then tumbled 79.59% in 2025.
  • A 5-year view of Leases shows it stood at $9.8 million in 2021, then dropped by 22.22% to $7.6 million in 2022, then dropped by 28.87% to $5.4 million in 2023, then tumbled by 48.75% to $2.8 million in 2024, then tumbled by 74.6% to $708000.0 in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Leases are $708000.0 (Q3 2025), $1.4 million (Q2 2025), and $2.1 million (Q1 2025).